MedTrace Logo

Fimasartan Achieving SBP Target (FAST) Study

NCT02495324 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 369

Last updated 2017-07-05

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of Fimasartan compared to Valsartan and Olmesartan(reference group) in patients with mild to moderate essential hypertension. Patients have 2 weeks of placebo run-in and wash out period, 2 weeks of taking required dose and 4 weeks of taking double dose.

Conditions

  • Essential,Hypertension

Interventions

DRUG

Placebo

2 weeks of placebo PO daily

DRUG

Fimasartan

60mg 1 tab PO daily for 2 weeks and 120mg 1 tab PO daily for 4 weeks

DRUG

Valsartan

80mg 1 tab PO daily for 2 weeks and 160mg 1 tab PO daily for 4 weeks

DRUG

Olmesartan medoxomil

10mg 1 tab PO daily for 2 weeks and 20mg 1 tab PO daily for 4 weeks

Sponsors & Collaborators

  • Boryung Pharmaceutical Co., Ltd

    lead INDUSTRY

Principal Investigators

  • KI-BAE SEUNG, Ph.D · Cardiovascular center, Seoul St.Mary's Hospital, The Catholic University of Korea

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2017-05-31
Completion
2017-05-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02495324 on ClinicalTrials.gov